UNSPSC 51283721: Cefotiam hexetil hydrochloride

This classification denotes a cephalosporin antibiotic C27H37N9O7S3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3N1X7E8CLE, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(2-amino-4-thiazolyl)acetyl)amino)-3-(((1-(2-(dimethylamino)ethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, hydrochloride (1:2), (6r,7r)-, but more generally known as cefotiam hexetil hydrochloride, which bears US NIH Compound Identifier 175647.

UNSPSC 51283721 Cefotiam hexetil hydrochloride, a Commodity code, nominally classifies a specific pharmaceutical active ingredient, but recent state and local activity under this code shows little direct purchasing of the named substance itself. Instead, state and local health departments and county health authorities are using the code to tag broader pharmaceutical procurement — including antibiotic tablets, naloxone, and drug deactivation systems — suggesting the code functions as a catch-all for specialized pharmaceutical inventory and public health supply chain management rather than as a narrow product classifier. The issuing bodies are state departments of public health and county health agencies pursuing these purchases through piggyback awards and competitive bidding to support emergency response, infectious disease management, and community health initiatives.

Geographic activity centers on Illinois and Florida, with the Illinois Department of Public Health awarding a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline hyclate and ciprofloxacin hydrochloride totaling $2,999,999.11 over three years under an Invitation for Bid, and Seminole County, Florida releasing an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The limited recent posting activity under this specific code and the significant scope divergence between the code's chemical name and the actual pharmaceutical products being procured suggests either mislabeling or sparse current demand; business development professionals should monitor this code for activity signals but expect infrequent or misclassified solicitations.